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anatomy, controversies remain in regard to the location, distribution and function of periprostatic 28 nerve fibers. Certainly, it is not possible to reproduce exactly the same dissection in every patient, 29 and therefore the surgeon has to find for each case the best balance between an oncologic safe 30 margin and the anatomical integrity of the nervous system ( Figure 6) . As anatomical knowledge 31 has increased, there has been a shift from the simplistic dichotomy "non-nerve sparing versus nerve 32 sparing" or "intra-inter-extra-fascial" towards the concept of "incremental nerve sparing" or cases (in 15 years) at the start of the trial. Thus, it can be argued that robotic surgery allowed the 2 less experienced surgeon to achieve equal outcomes significantly faster. This concept is also 3 supported by the findings from the study by Thompson et al, who analyzed over 1550 cases to 4 determine whether a well established open surgeon (over 3,000 cases) could achieve better 5 outcomes by switching to robotics. They found that, after a learning curve, the surgeon could indeed 6 improve, especially their functional outcomes 56 . 7 
New frontiers of prostate cancer surgery: oligometastatic cancer and nodal recurrent
8 cancer 9 Over the past years, oligometastatic cancer -clinically defined as disease with up to five 10 extra-pelvic lesion -as has been recognized as separate clinical entity from advanced cancer, mostly 11 thanks to the implementation of functional imaging 57 . A growing body of evidence seems to support 12 the hypothesis that a radical treatment to their primary tumor, alongside "metastasis-directed 13 therapy", might be beneficial for patients with oligometastatic cancer. These has been suggested by 14 recent large population-based studies, from both USA 58 and Europe 59 . Gandaglia et al reported on 15 the outcomes of a selected cohort of 11 patients with oligometastatic disease treated with radical 16 prostatectomy and extended pelvic lymph node dissection. Adjuvant androgen deprivation therapy 17 was administered to 10 patients (91%). The 7-yr clinical progression-free and cancer specific 18 survival survival rates were 45% and 82%, respectively 60 . Ongoing trials. whose findings will be 19 available within the next few years, will better define the best approach for oligometastatic prostate 20 cancer ( Table 4 ) (www.clinicaltrials.gov). 21 Salvage lymph node dissection has been recently proposed as possible treatment option in 22 selected prostate cancer patients with disease recurrence limited to regional and/or retroperitoneal 23 nodes 61 . This novel therapeutic approach has become available due to recent advances in the field 24 of nuclear medicine imaging modalities, such as PET/CT and PET/MRI 62 . Several centers have 25 reported initial series with encouraging results ( Table 5) [63] [64] [65] [66] [67] , but further clinical investigation is 26 required. 27 28 Focal therapy has been conceived as a minimally invasive tissue-preserving treatment 29 strategy for localized prostate cancer 68 . The rationale supporting this strategy is mainly based on the concept of "index lesion", and on the increased ability to detect this lesion (and to rule out high risk lesions) thanks to the standardization of MRI imaging-based biopsy techniques 69 . Table 6 ). Among these, HIFU 6 and cryotherapy are those that have been mostly implemented in clinical practice. However, 7 evidence supporting the use of newer technologies, such as PDT, in low risk cancer is being 8 reported in large scale phase III studies 71 . 
Focal therapy for prostate cancer

M A N U S C R I P T A C C E P T E D
BLADDER CANCER
11
Urothelial bladder cancer represents a complex disease with a high prevalence, and high 12 morbidity and mortality if not optimally treated 72 . Traditionally, its best surgical treatment depends 13 on the stage of the disease: for non muscle invasive cancer, transurethral resection (TURB) 14 followed by induction and maintenance immunotherapy with intravesical BCG or chemotherapy 15 represents the current standard 73 ; for muscle-invasive cancer, radical cystectomy with neoadjuvant 16 chemotherapy offers the best chance for cure, whereas in selected patients bladder-sparing 17 modalities, consisting of transurethral resection with chemo-radiation, can be considered 74 .
18
Over the past decade, two major areas of research in the field of bladder surgery have been 19 investigated, that of new optimal imaging technologies for non muscle invasive disease, and that of 20 robotic surgery for the management of muscle invasive disease. 
Innovations in optical imaging technology 22
Precision surgery for bladder cancer patients mostly relies on initial diagnostic endoscopic 23 accuracy. The current standard "white light cystoscopy" presents significant shortcomings, 24 including suboptimal detection of flat lesion (carcinoma in situ), inaccurate tumor delineation to 25 facilitate complete resection, challenging differential diagnosis with inflammatory lesions, and 26 difficult determination of grade and stage. Therefore, novel technologies have been developed and 27 implemented to aid the surgeon during endoscopic management of bladder cancer 75 . These can be [CLE]; optical coherence tomography [OCT]) ones. 31 PDD is also known as "fluorescence" or "blue light" cystoscopy. It requires preoperative 32 intravesical administration of a contrast agent (a protoporphyrin analogue), a blue light (380-480 M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 8 nm) source, and specialized lens and camera. PDD has been implemented in Europe for the past 1 two decades using 5-aminolevulinic acid (5-ALA). Its derivative hexaaminolevulinate (HAL; 2 Hexvix ® /Cysview ® ) has become more recently available and it was approved by the FDA in 2010 3 on the basis of a phase III trial showing a 16% reduction in rate of recurrence at 9 months versus 4 white light cystoscopy 76 . PDD seems to provide a better detection of both papillary and flat 5 appearing CIS lesions. Burger et al reported a meta-analysis of raw data from prospective studies on 6 1345 patients, and they found that PDD detected significantly more Ta tumors (14.7%) and CIS 7 lesions (40.8%) than standard cystoscopy. Moreover, about 25% patients with at least one 8 additional Ta/T1 tumor was identified when using PDD, and in 26.7% of patients, CIS was detected 9 only by PDD. Overall, recurrence rates up to 12 months were significantly lower with PDD (34.5% 10 versus 45.4%) 77 . However, a prospective randomized multicenter study found no significant 11 difference in tumor recurrence and progression when using PDD 78 . In another pooled analysis of 3 12 phase III multicenter trials detection rate for CIS was 87% with PDD and 75% for standard 13 cystoscopy 79 . However, no data to date have suggested that use of PDD translates into a reduction 14 in disease progression. False positive can be regarded as a drawback of the technology, as they 15 occur in 10-12% of patients 76 . 16 NBI is a technology that filters out the red spectrum of white light resulting in blue and 17 green spectra that are preferentially absorbed by hemoglobin, thus enhancing the mucosal and sub- Overall, 965 patients were enrolled in the study (481 underwent -assisted TURB and 484 received 29 NBI-assisted TURB). In patients at low risk for disease recurrence, recurrence rates at 12 months 30 were significantly lower in the NBI group (5.6% versus 27.3%; p=0.002) 83 . Similar results can be 
Sexual and organ preserving approaches for radical cystectomy (RC)
17
Open RC with pelvic lymph node dissection still represents the gold standard treatment for 18 non-metastatic muscle-invasive and selected high-risk non muscle-invasive bladder cancer 88 . With 19 better understanding of neuro-functional anatomy, sexual-preserving RC techniques have been 20 developed over the years in order to achieve superior functional outcomes, in both male and female 21 patients with bladder cancer 89 ( Table 7) . Long-term data on "prostate sparing" RC have shown that 22 this can be an oncologically safe procedure with excellent functional results in a subset of carefully 23 selected patients 90 . "Seminal vesicle" cystoprostatectomy also resulted in a high probability of 24 preserving potency, without putting patients at unnecessary risk 91 . "Nerve sparing" radical 25 cystoprostatectomy also showed to not compromise cancer control while providing improved 26 postoperative quality of life 92,93 . In female patients, genital sparing cystectomy (with preservation of 27 the uterus, vagina and ovaries) is feasible in selected women, and it can provide good functional 28 outcome, better sexual function, and favorable oncological outcome 94 . A "nerve sparing" technique 29 in female patients has also been obtained by avoiding damage to the proximal urethra and to 30 preserve the autonomic innervation of the rhabdosphincter 95 . 25 Since radical cystecotmy represents a cancer surgery, oncological outcomes remain a 26 primary concern. Only few series of minimally invasive radical cystectomy with long term 4 Despite a rising incidence, the mortality of RCC in developed countries has been stable over 5 the last decade 109 . This phenomenon can be explained by the significant advances in the 6 management of the disease, including refinements in renal biopsy techniques 110 , implementation of 7 active surveillance protocols 111 , and adoption of minimally invasive nephron-sparing surgery 8 procedures 112 . This has resulted into a paradigm shift, which is the idea of tailoring the treatment to 9 each specific case with the ultimate aim of achieving the best oncological outcome and the maximal 10 functional preservation. This process has been facilitated by the application of new technologies, 11 allowing a better surgical planning, within the realm of "precision surgery". failing to demonstrate a survival benefit for partial nephrectomy despite improved renal functional 23 outcomes in the partial nephrectomy arm 118,119 .
KIDNEY CANCER
24
Despite the oncological equivalence to radical nephrectomy and renal functional benefit, PN 25 has been regarded as a higher risk procedure with increased risk of urinary fistulae and procedure 26 specific complications. This paradigm may be shifting however, with the increasing adoption of the 27 robotic platform. Recent data suggest that robotic technology may enable surgeons across different 28 practice settings to perform nephron-sparing surgery more frequently 120 .
29
The robotic approach offers the option of a minimally invasive PN recapitulating the safety (Table 8) . 30 Overall, probe-ablative therapy provides an attractive nephron-sparing treatment for small 31 renal masses in older patients with significant medical co-morbidities who are poor candidates for 
